The overall objective of GBA is to:

Develop, promote, and support non-commercial biofoundries established around the world,
Intensify collaboration and communication among biofoundries,
Collectively develop responses to technological, operational, and other types of common challenges,
Enhance visibility, impact and sustainability of non-commercial biofoundries, and
Explore globally relevant and societally impactful grand challenge collaborative projects.

(1) DOE Agile BioFoundry (pending) located across Emeryville, CA, Richland, WA, Golden, CO, Lemont, IL, Los Alamos, NM, Oak Ridge, TN, and Idaho Falls, ID sites; (2) Illinois Biological Foundry for Advanced Biomanufacturing (iBioFAB), University of Illinois at Urbana-Champaign; (3) Concordia Genome Foundry, Concordia University Montreal; (4) DAMP lab, Boston University; (5) Edinburgh Genome Foundry, University of Edinburgh; (6) Earlham Institute, Norwich Research Park; (7) London DNA Foundry, Imperial College London; (8) SYNBIOCHEM, University of Manchester; (9) GeneMill University of Liverpool; (10) Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark; (11) Frontier Science Center for Synthetic Biology (MOE), Tianjin University; (12) Graduate School of Science, Technology and Innovation, Kobe University; (13) Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; (14) NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), National University of Singapore; (15) Australian Foundry for Advanced Biomanufacturing (AusFAB), University of Queensland and (16) Australian Genome Foundry, Macquarie University.